MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Pertuzumab (PBS)

CAS No. : 380610-27-5

MCE 站：Pertuzumab (PBS)

产品活性：Pertuzumab (PBS) 是一种人源化单克隆抗体，是一种 HER2 二聚抑制剂。可用于转移性 HER2 阳性乳腺癌的研究。

研究领域：JAK/STAT Signaling  |  Protein Tyrosine Kinase/RTK

作用靶点：EGFR

In Vitro: Trastuzumab ａnd Pertuzumab are highly synergistic inhibitors of BT474 breast cancer cell survival. The combination of trastuzumab ａnd Pertuzumab mediates a loss of up to 60% of cells at doses in which individual drugs do not alter cell survival. The combination of trastuzumab ａnd Pertuzumab reduces the percentage of proliferating (S-phase) cells by more than 2-fold. A combination of trastuzumab ａnd Pertuzumab inhibits cell proliferation ａnd survival to a greater degree than does either agent alone.

In Vivo: In Calu-3 NSCLC xenografts, monotherapy with pertuzumab or trastuzumab is able to significantly inhibit tumor growth, with treatment-to-control ratios (TCR) of 0.23 ａnd 0.27, respectively. The combination of trastuzumab ａnd pertuzumab produces a dramatically enhanced antitumor activity compared with single-agent treatments (TCR 0.05, resulting in tumor regression and, in 3 of 10 animals, complete tumor remission). Treatment of KPL-4 breast cancer xenografts with either trastuzumab or pertuzumab inhibits tumor growth with TCRs of 0.67 ａnd 0.65, respectively. Pertuzumab maintains antitumor activity after progression on trastuzumab.

相关产品：Osimertinib  |  Gefitinib  |  Trastuzumab  |  Erlotinib  |  Cetuximab  |  Afatinib  |  AG490  |  Lapatinib  |  Neratinib  |  Tucatinib  |  Genistein  |  Dacomitinib  |  AG-1478  |  Poziotinib  |  Pertuzumab  |  BI-4020  |  Mobocertinib  |  Sapitinib  |  Pyrotinib  |  CUDC-101  |  Gefitinib-based PROTAC 3  |  TAS6417  |  NSC 228155  |  Mubritinib  |  Pelitinib

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。